InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$285.42

2026-10-16

Market Cap

$504.4B

Volume

5.6M

52-Wk High

$291.40

52-Wk Low

$190.75

Trailing PE

80.4

P/S

7.83

Gross Margin

71.5%

Net Margin

9.8%

ROE

-136%

ROIC

13%

Piotroski

9/9

Altman Z

2.7

1-Yr Return

+25.8%

5-Yr Return

+459.3%

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

SectorHealthcareIndustryDrug Manufacturers - GeneralExchangeNYSEMarket Cap$504.4BEmployees57,000 (SEC-filed)CEORobert A. MichaelIPO2013-01-02CountryUS

1 North Waukegan Road, North Chicago, IL 60064-6400 · Tel 847 932 7900 · abbvie.com

INSIDERSTREET SCORE67 / 100Street mean $299.50 (12 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$19M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · ABBV +25.8% · S&P 500 +15.9% · spread +9.9pp

7 Years vs S&P 500 · ABBV +459.3% · S&P 500 +189.9% · spread +269.5pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE67of 100

Score Breakdown

Profitability	62/100
Growth	76/100
Momentum	91/100
Quality	72/100
Earnings Quality	59/100
Balance Sheet	26/100
Value	32/100
Risk (safety)	50/100
Overall	66.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
JNJ	64
MRK	49
NVS	65
AZN	71
AMGN	67
LLY	78
ABBV	67

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 67 in 26 Q2, latest 67 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY67 / 100IS Score 66.6 / 100 · +0.0 from peak of 67

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 93 / 100 · Power +86 · 22 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 67 and price structure at 93 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 66.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 56 → 64 → 58 → 67	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 4,196 → now 4,196	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)1 buys2026-05-01

Insider Buys (180d)0none disclosed

ETF Funds (30d)1820 up / 1601 downnet +219 funds

Institutions Added (13F)124managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 4,196 · latest 4,196 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	4,196	1342.6M	$329.3B	75.8%
2026 Q1	4,072	1297.3M	$275.3B	73.2%
2025 Q4	4,118	1313.7M	$294.4B	74.2%
2025 Q3	3,858	1266.5M	$287.6B	71.5%
2025 Q2	3,734	1288.6M	$234.3B	72.8%
2025 Q1	3,767	1283.0M	$265.2B	72.5%
2024 Q4	3,694	1272.3M	$222.6B	71.8%
2024 Q3	3,442	1265.0M	$244.4B	71.4%
2024 Q2	3,311	1260.1M	$211.7B	71.2%
2024 Q1	3,323	1250.8M	$222.7B	70.6%
2023 Q4	3,267	1235.6M	$188.3B	69.8%
2023 Q3	3,050	1222.3M	$179.0B	69.0%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Quaggin Susan E	director	2026-09-30	A-Award	59	$0.02M	918
Rapp Edward J	director	2026-09-30	A-Award	129	$0.03M	29,568
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2026-08-14	EXERCISE	32,710	$2.58M	107,140
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2026-08-14	SELL	32,710	$8.18M	74,430
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	2026-08-14	EXERCISE	32,710	$2.58M	0
Rapp Edward J	director	2026-06-30	A-Award	134	$0.03M	29,236
Quaggin Susan E	director	2026-06-30	A-Award	62	$0.02M	853
Falk Thomas J	director	2026-05-08	A-Award	1,118	—	2,321

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	6	78,989	$18.9M	Counted
M — Exercises (paired A/D)	4	55,091	$6.4M	None — mechanics
F — Tax withholding	10	140,437	$32.6M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$18.9M6 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-14	Nicholas Donoghoe	32,710	$8.2M
2026-05-26	Robert J Alpern	13,000	$2.8M
2026-03-06	David R. Purdue	5,230	$1.2M
2026-03-02	Perry C Siatis	18,668	$4.4M
Trailing 12 mo	5 filings	91,989	$22M

Filed	Form	Reporting person	% of class	Shares
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-07-07	SCHEDULE 13G/A	The Vanguard Group	10.03%	177.3M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Pete Sessions	House	SELL	$15,001 - $50,000	2026-09-14	2026-09-21
Ro Khanna	House	SELL	$15,001 - $50,000	2026-09-04	2026-10-09
Josh Gottheimer	House	SELL	$1,001 - $15,000	2026-05-05	2026-06-04
John Boozman	Senate	SELL	$1,001 - $15,000	2025-08-22	2025-09-13
John Boozman	Senate	SELL	$1,001 - $15,000	2025-08-22	2025-09-12
John Boozman	Senate	SELL	$1,001 - $15,000	2025-08-22	2025-09-12

House 12-Mo22 trades3 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)4,072

13F Shares1.30B73.2% of shares out

New / Closed206 / 180positions, QoQ

Increased / Reduced1,722 / 1,685positions, QoQ

Put/Call (13F)0.98option positions

Free Float99.8%1.76B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	1.7M	$443M
Wealth Enhancement Advisory Servic	763,184	$180M
Hamlin Capital Management, Llc	728,805	$191M
Ferguson Wellman Capital Managemen	658,136	$172M
Mn Services Vermogensbeheer B.V.	522,459	$137M
Fjarde Ap-Fonden /Fourth Swedish N	513,338	$134M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.6%	$14.7B
VTSAX	0.6%	$14.7B
VSMPX	0.6%	$14.7B
VTI	0.6%	$14.7B
VFFSX	0.7%	$12.1B
VFIAX	0.7%	$12.1B

13F Filers Holding ABBV — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session39.5%2026-10-15

20-Day Avg48.0%50-day 50.3%

TrendFalling20d vs 50d

By Market CenterQ: 39% · N: 40% · B: 46%latest session

Weekly Notional ($B)

Where ABBV Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	6.5M	56 sh
Ubsa Ubs Ats	5.5M	60 sh
Ebxl Level Ats	3.8M	42 sh
Sgmt Sigma X2	3.8M	56 sh
Mspl Ms Pool (Ats-4)	3.3M	170 sh
Pure Purestream	2.8M	62 sh

Where a dollar of AbbVie Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$46.6B	95%
Non-US	$2.4B	5%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

ABBV (live moat model)Peer median: JNJ · MRK · NVS · AZN · AMGN

Component scores from the live moat model. Peer median illustrative.

Moat score 61/100 — Narrow; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Robert A. Michael	Chief Executive Officer & Chairman of the Board
Jeffrey Ryan Stewart	Executive Vice President & Chief Commercial Officer
Azita Saleki	Executive Vice President & Chief Operating Officer
Scott T. Reents	Executive Vice President & Chief Financial Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+2.9%

Next Report2026-10-30

Income Quality3.09OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+22.7%	+3.3%	-6.4%	+3.7%	+8.6%
Gross profit	+27.4%	+4.9%	-16.6%	+16.3%	+29.8%
Operating income	+57.7%	+1.1%	-29.6%	-28.4%	+132.2%
Net income	+150.0%	+2.5%	-58.9%	-12.0%	-1.2%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	56.2	58.1	54.3	56.3	61.2
Cost of revenue	17.4	17.4	20.4	16.9	10.0
Gross profit	38.8	40.6	33.9	39.4	51.2
R&D expense	8.0	6.5	7.7	12.8	9.1
SG&A expense	12.3	15.3	12.9	13.2	14.0
Operating income	17.9	18.1	12.8	9.1	21.2
EBITDA	23.9	24.2	17.2	14.9	28.3
D&A	8.5	8.5	8.7	8.4	19.1
Pretax income	13.0	13.5	6.2	3.7	6.6
Income tax	1.4	1.6	1.4	-0.6	2.4
Net income	11.5	11.8	4.9	4.3	4.2
Diluted EPS ($)	6.45	6.63	2.72	2.39	2.36
Diluted shares (M)	1,777	1,778	1,773	1,773	1,791

Operating CF$19B

CapEx$1B

Free cash flow$18B

SBC$1B

Buybacks$1B

Net cash change$-0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	9.2	12.8	5.5	5.2
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	11.3	11.2	10.9	12.6
Total current assets	28.5	33.0	25.6	29.1
PP&E (net)	4.9	5.0	5.1	6.4
Goodwill + intangibles	99.6	87.9	95.0	88.3
Total assets	138.8	134.7	135.2	134.0
Accounts payable	2.9	3.7	2.9	3.6
Short-term debt	4.3	7.2	6.8	8.7
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	29.5	37.8	38.7	43.3
Long-term debt	59.1	52.2	60.3	59.6
Total liabilities	121.5	124.3	131.8	137.2
Shareholders' equity	17.3	10.4	3.4	-3.2

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	11.8	4.8	4.3	4.2
D&A	8.5	8.7	8.4	8.1
Stock-based compensation	0.7	0.7	0.9	1.0
Working capital change	(0.3)	2.8	(2.8)	(2.4)
Operating cash flow	24.9	22.8	18.8	19.0
Capital expenditures	(0.7)	(0.8)	(1.0)	(1.2)
Investing cash flow	(0.6)	(2.0)	(20.8)	(6.6)
Buybacks	(1.5)	(2.0)	(1.7)	(1.0)
Dividends paid	(10.0)	(10.5)	(11.0)	(11.7)
Debt issuance / (repay)	(12.4)	(4.1)	7.4	(0.3)
Financing cash flow	(24.8)	(17.2)	(5.2)	(12.7)
Free cash flow	24.2	22.1	17.8	17.8

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	81.0%	72.5%	35.2%	62.5%	15389.1%	-136%
ROA	7.8%	8.3%	3.6%	3.2%	3.1%	4.7%
ROIC	19.2%	22.0%	17.2%	16.1%	18.3%	13.5%
Gross margin	69.0%	70.0%	62.4%	70.0%	83.7%	71.5%
Operating margin	31.9%	31.2%	23.5%	16.2%	34.7%	29.3%
Net margin	20.5%	20.4%	9.0%	7.6%	6.9%	9.8%
EBITDA margin	42.6%	41.6%	31.6%	26.5%	46.3%	32.9%
FCF margin	39.1%	41.8%	40.6%	31.7%	30.6%	—
VALUATION
P/E	17.99	21.75	52.64	71.16	95.78	80.4
P/B	13.47	14.92	24.71	91.56	-123.96	-85.2
P/S	3.69	4.43	4.71	5.40	6.63	7.83
P/FCF	9.44	10.62	11.60	17.07	21.67	27.7
EV/EBITDA	11.50	12.92	17.66	24.59	26.61	26.8
EV/Revenue	4.90	5.38	5.58	6.51	7.67	8.8
Earnings yield	5.6%	4.6%	1.9%	1.4%	1.0%	1.25%
FCF yield	10.6%	9.4%	8.6%	5.9%	4.6%	3.61%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	0.79	0.96	0.87	0.66	0.67	0.81
Quick ratio	0.70	0.84	0.76	0.55	0.56	0.69
Debt / equity	5.03	3.72	5.80	20.40	-21.12	-11.93
Debt / assets	52.9%	46.2%	44.6%	50.2%	51.6%	52.4%
Net debt / EBITDA	2.83	2.27	2.75	4.18	3.62	3.03
Interest coverage	6.36	7.04	3.81	2.32	3.28	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.38	0.41	0.40	0.42	0.45	0.48
Receivables turnover	5.98	5.47	4.85	5.10	5.20	4.7
DSO (days)	61	67	75	72	70	78
DPO (days)	54	61	59	72	73	659
Cash conversion cycle	74	76	85	89	99	-479
GROWTH (YoY)
Revenue growth	22.7%	3.3%	-6.4%	3.7%	8.6%	—
Net income growth	150.0%	2.5%	-58.9%	-12.0%	-1.1%	—
EPS growth	150.5%	2.5%	-58.8%	-12.1%	-1.1%	—
FCF growth	31.0%	10.3%	-9.0%	-19.2%	4.9%	—
PER SHARE ($)
EPS (diluted, TTM)	6.49	6.66	2.74	2.41	2.39	3.57
Book value / share	8.67	9.70	5.85	1.88	-1.84	-3.31
Revenue / share	31.61	32.65	30.65	31.77	34.48	36.36
FCF / share	12.37	13.64	12.45	10.06	10.54	10.28
Cash / share	5.53	5.19	7.23	3.13	2.96	3.71
SHAREHOLDER RETURN & SCORES
Buyback yield	0.4%	0.6%	0.8%	0.6%	0.2%	0.34%
Altman Z-Score	1.65	2.10	1.79	1.76	2.17	2.7
Piotroski F-Score	8	9	5	5	6	9/9
Beneish M-Score	-2.77	-2.85	-3.03	-3.02	-2.94	-2.82

Model	Score	Zone	Note
Piotroski F-Score	9 / 9	Strong
Altman Z-Score	2.7	Grey zone	Grey
Income quality	3.09	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.82	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.73
Interest burden	0.65
Operating margin	20.7%
Asset turnover	0.47×
Financial leverage	-44.51×
= ROE	-206%

Growth Quality (live)	Value
Revenue stability	0.72
Earnings stability	0.30
Earnings persistence	0.50
Revenue CAGR 3y	4.7%
EPS CAGR 3y	-10.1%
FCF CAGR 3y	-8.3%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield0.34%

Dividend Yield2.42%

Total Shareholder Return2.84%cash yield

SBC / Revenue1.5%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
JNJ	$615.9B	38.7	26%	21.9%	+8.1%	7/9	+33.9%
MRK	$360.1B	115.8	7%	-8.0%	+4.5%	4/9	+75.4%
NVS	$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
AZN	$256.5B	24.7	22%	16.3%	+8.6%	9/9	-1.5%
AMGN	$233.8B	26.7	91%	23.6%	+9.2%	8/9	—
LLY	$1,183.3B	42.1	102%	30.9%	+49.6%	9/9	—
GILD	$193.7B	-60.1	-21%	—	+5.5%	5/9	—
PFE	$168.6B	39.1	5%	-1.6%	-0.2%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

44 Analysts

Str Sell (0)Sell (1)Hold (11)Buy (32)Str Buy (0)

Mean Target (qtr)$299.5012 targets

Target vs. Price+4.9%last-quarter mean

Next Report2026-10-30street $3.74

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$67.63B	$67.98B / $67.49B	$13.95	$14.23 / $13.79	15
FY2027	$73.50B	$74.87B / $71.86B	$16.38	$17.37 / $15.52	14
FY2028	$79.00B	$81.64B / $75.17B	$17.88	$20.89 / $15.47	8

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$306.67	+7.4%	3
Last Quarter	$299.50	+4.9%	12
Last Year	$275.07	-3.6%	42
All Time	$222.76	-22.0%	98

Rolling mean of published targets vs. last close $285.42. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

C

DCF

3/5

ROE

1/5

ROA

4/5

Debt/Eq

1/5

P/E

1/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

ABBV +25.8% vs S&P 500 +15.9% — spread +9.9pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$269.02	+16.40	+6.10%	Above
SMA 50	$262.09	+23.33	+8.90%	Above
SMA 200	$233.59	+51.83	+22.19%	Above
EMA 9	$276.93	+8.49	+3.07%	Above
EMA 21	$270.65	+14.77	+5.46%	Above
EMA 50	$262.79	+22.63	+8.61%	Above
EMA 200	$239.31	+46.11	+19.27%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +8622 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%100

Volume 20%94

Volatility 10%100

Patterns 15%62

This Week100% bullishof 11 price-based votes

4 Weeks Ago100%+0 pts since

12 Weeks Ago100%+0 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$269.02

Price vs SMA 50$262.09

Price vs SMA 200$233.59

EMA 9/21 Cross276.9/270.6

SMA 50/200Golden

ADX DirectionADX 28

Supertrend$266

Parabolic SAR$267

SMA Slope1.070

RSI71.1

Stochastic K/D84/83

StochRSI K/D87/80

Williams %R-17

CCI167

TSI vs Signal31.1

CMO42.2

ROC9.26%

OBV SignalAccum

Chaikin MF0.100

MFI61

Force Index10M

Elder Ray Bull15.99

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 83

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$285.87 / $288.93 / $294.46	S1 / S2	$280.34 / $277.28
Bollinger (20,2)	$253.40 – $284.64	Squeeze	Off
52-wk range	$190.75 – $291.40	Off 52-wk high	-2.0%
ATR (14)	$6.46 (2.3%)	Historical vol	19.7%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

-1.1%Jan36%

+3.3%Feb71%

-0.8%Mar57%

+2.6%Apr62%

-0.4%May31%

+1.4%Jun62%

+1.4%Jul62%

+0.3%Aug46%

+2.3%Sep54%

+1.0%Oct62%

+4.9%Nov69%

+2.9%Dec69%

Sample: 14 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	ABBV	S&P 500
Weekly volatility (σ, 1y)	3.32%	1.83%
Best / worst week (1y)	+6.9% / -8.5%	—
Max drawdown (5y, monthly)	-27.0%	—
1-week VaR (95%)	-5.4%	—
Beta (5y)	0.28	1.00

ABBV EQUITY WEATHER (LIVE)PARTLY CLOUDY · +30

Trend+51

Momentum+65

Volume+51

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 812 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+29.6+39.1 vs industry

Trend+50.5+54.6 vs industry

Momentum+65.3+55.4 vs industry

Volume+50.8+34.2 vs industry

Reading	ABBV	Drug Manufacturers - General n=150	Healthcare n=5,272	All US symbols n=70,435
Overall	+29.6	-9.5	-24.0	-20.5
Trend	+50.5	-4.1	-25.6	-21.3
Momentum	+65.3	+9.9	-28.5	-15.8
Volume	+50.8	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Robert A. Michael Chairman of the Board and	$32.5M	57% equity+incentive
Jeffrey R. Stewart Executive Vice President,	$15.4M	54% equity+incentive
Scott T. Reents Executive Vice President, Ch	$12.4M	54% equity+incentive
Azita Saleki-Gerhardt Executive Vice Preside	$10.8M	57% equity+incentive
Roopal B. Thakkar Executive Vice President,	$9.9M	64% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	63
Social	62
Governance	69
Composite ESG	65

Composite ESG Trend

Filed	8-K contents	Items
2026-10-15	Officer/Director Change	5.02
2026-10-05	Earnings Release; Exhibits	2.02,9.01
2026-09-03	Regulation FD; Exhibits	7.01,9.01
2026-08-18	Other Events; Exhibits	8.01,9.01
2026-08-05	Other Events; Exhibits	8.01,9.01
2026-07-31	Earnings Release; Exhibits	2.02,9.01
2026-07-06	Earnings Release; Exhibits	2.02,9.01
2026-06-22	Regulation FD; Exhibits	7.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-30 to 2026-07-31
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	63 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-05-08 to 2026-09-30
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	2 rows · 2025-07-07 to 2026-03-26
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

AbbVie Inc. (ABBV)

Institutions holding — 12 quarters

AbbVie Inc. (ABBV)

Monthly Net Insider Flow (000 shares)

Signal Summary

AbbVie Inc. (ABBV)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding ABBV — quarterly

Institutional Put/Call — quarterly

AbbVie Inc. (ABBV)

Where ABBV Trades in the Dark

AbbVie Inc. (ABBV)

3.8 · Employees (SEC filings)

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

Balance Sheet — Full

Cash Flow Statement — Full

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

Street Price Target — Trajectory

Third-Party Composite Rating

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

Family Scores (site weights)

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)

AbbVie Inc. (ABBV)